Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trialSara Lonardi, Gerardo Rosati, Maria Di Bartolomeo et al.|Annals of Oncology|2016Cited by 56
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Rossana Berardi, Gerardo Rosati et al.|European Journal of Cancer|2017Cited by 30
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Giordano Beretta, Sara Lonardi et al.|European Journal of Cancer|2021Cited by 15
Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?Paolo Carlini, Francesco Cognetti, G. Ferretti et al.|The Journal of Steroid Biochemistry and Molecular Biology|2003Cited by 11
2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)Stefano Cascinu, Irene Floriani, Sara Lonardi et al.|European Journal of Cancer|2015Cited by 5